Truist Securities Downgrades IGM Biosciences to Hold, Lowers Price Target to $12
Portfolio Pulse from Benzinga Newsdesk
Truist Securities has downgraded IGM Biosciences from Buy to Hold and reduced its price target from $24 to $12.
October 01, 2024 | 1:10 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Truist Securities downgraded IGM Biosciences from Buy to Hold, reducing the price target from $24 to $12, indicating a less optimistic outlook.
The downgrade from Buy to Hold and the significant reduction in the price target from $24 to $12 by Truist Securities suggests a negative short-term outlook for IGM Biosciences. This is likely to put downward pressure on the stock price as investors adjust to the new expectations.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100